Obesity and liver cancer

Clinics in Liver Disease

Volumn 18, Issue 1, 2014, Pages 191-203

  Vanni, Ester ^a   Bugianesi, Elisabetta ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

Carcinogenesis; Hepatocellular carcinoma; Nonalcoholic fatty liver disease; Obesity

Indexed keywords

CANCER RECURRENCE; CANCER RISK; CHRONIC LIVER DISEASE; HUMAN; INTESTINE FLORA; LIPOTOXICITY; LIVER CARCINOGENESIS; LIVER CELL; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; NONALCOHOLIC FATTY LIVER; OBESITY; RADIOFREQUENCY ABLATION; REVIEW; STELLATE CELL; WAIST HIP RATIO;

CARCINOGENESIS; HEPATOCELLULAR CARCINOMA; NONALCOHOLIC FATTY LIVER DISEASE; OBESITY;

CARCINOMA, HEPATOCELLULAR; FATTY LIVER; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MODELS, BIOLOGICAL; OBESITY; RISK FACTORS; SIGNAL TRANSDUCTION;

EID: 84888065738     PISSN: 10893261     EISSN: 15578224     Source Type: Journal    
DOI: 10.1016/j.cld.2013.09.001     Document Type: Review

References (69)

1. World Health Organization. Obesity 2008. Available at: Accessed October 22, 2009. http://www.who.int/topics/%20obesity/en/.
2. Ogden C.L., Carroll M.D., Flegal K.M. High body mass index for age among US children and adolescents, 2003-2006. JAMA 2008, 299:2401-2405.
3. Nader P.R., O'Brien M., Houts R., et al. Identifying risk for obesity in early childhood. Pediatrics 2006, 118:e594-e601.
4. Singh A.S., Mulder C., Twisk J.W., et al. Tracking of childhood overweight into adulthood: a systematic review of the literature. Obes Rev 2008, 9:474-488.
5. Calle E.E., Rodriguez C., Walker-Thurmond K., et al. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S adults. NEngl J Med 2003, 348:1625-1638.
6. Vongsuvanh R., George J., Qiao L., et al. Visceral adiposity in gastrointestinal and hepatic carcinogenesis. Cancer Lett 2013, 330:1-10.
7. Boeing H. Obesity and cancer-the update 2013. Best Pract Res Clin Endocrinol Metab 2013, 27:219-227.
8. El-Serag H.B. Hepatocellular carcinoma. NEngl J Med 2011, 365:1118-1122.
9. Welzel T.M., Graubard B.I., Zeuzem S., et al. Metabolic syndrome increases the risk of primary liver cancer in the United States: a study in the SEER-Medicare database. Hepatology 2011, 54:463-471.
10. Alberti K.G., Zimmet P., Shaw J. Metabolic syndrome-a new world-wide definition. A consensus statement from the International Diabetes Federation. Diabet Med 2006, 23:469-480.
11. Bugianesi E., Vanni E., Marchesini G. NASH and the risk of cirrhosis and hepatocellular carcinoma in type 2 diabetes. Curr Diab Rep 2007, 7:175-180.
12. Larsson S.C., Wolk A. Overweight, obesity and risk of liver cancer: a meta-analysis of cohort studies. Br J Cancer 2007, 97:1005-1008.
13. Renehan A.G., Tyson M., Egger M., et al. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 2008, 371:569-578.
14. Saunders D., Seidel D., Allison M., et al. Systematic review: the association between obesity and hepatocellular carcinoma-epidemiological evidence. Aliment Pharmacol Ther 2010, 31:1051-1063.
15. Schlesinger S., Aleksandrova K., Pischon T., et al. Abdominal obesity, weight gain during adulthood and risk of liver and biliary tract cancer in a European cohort. Int J Cancer 2013, 132:645-657.
16. Ohki T., Tateishi R., Shiina S., et al. Visceral fat accumulation is an independent risk factor for hepatocellular carcinoma recurrence after curative treatment in patients with suspected NASH. Gut 2009, 58:839-844.
17. Sanyal A., Poklepovic A., Moyneur E., et al. Population-based risk factors and resource utilization for HCC: US perspective. Curr Med Res Opin 2010, 26:2183-2191.
18. Matteoni C.A., Younossi Z.M., Gramlich T., et al. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999, 116:1413-1419.
19. Ekstedt M., Franzén L.E., Mathiesen U.L., et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 2006, 44:865-873.
20. Söderberg C., Stål P., Askling J., et al. Decreased survival of subjects with elevated liver function tests during a 28-year follow-up. Hepatology 2010, 51:595-602.
21. Arase Y., Kobayashi M., Suzuki F., et al. Difference in malignancies of chronic liver disease due to non-alcoholic fatty liver disease or hepatitis C in Japanese elderly patients. Hepatol Res 2012, 42:264-272.
22. Dam-Larsen S., Becker U., Franzmann M.B., et al. Final results of a long-term, clinical follow-up in fatty liver patients. Scand J Gastroenterol 2009, 44:1236-1243.
23. Ong J.P., Pitts A., Younossi Z.M. Increased overall mortality and liver-related mortality in non-alcoholic fatty liver disease. JHepatol 2008, 49:608-612.
24. Yatsuji S., Hashimoto E., Tobari M., et al. Clinical features and outcomes of cirrhosis due to non-alcoholic steatohepatitis compared with cirrhosis caused by chronic hepatitis C. JGastroenterol Hepatol 2009, 24:248-254.
25. Bugianesi E., Leone N., Vanni E., et al. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 2002, 123:134-140.
26. Sanyal A.J., Banas C., Sargeant C., et al. Similarities and differences in outcomes of cirrhosis due to nonalcoholic steatohepatitis and hepatitis C. Hepatology 2006, 43:682-689.
27. Sorensen H.T., Friis S., Olsen J.H., et al. Risk of liver and other types of cancer in patients with cirrhosis: a nationwide cohort study in Denmark. Hepatology 1998, 28:921-925.
28. Ascha M.S., Hanouneh I.A., Lopez R., et al. The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology 2010, 51:1972-1978.
29. Bugianesi E. Non-alcoholic steatohepatitis and cancer. Clin Liver Dis 2007, 11:191-207.
30. Kawai H., Nomoto M., Suda T., et al. Multicentric occurrence of hepatocellular carcinoma with nonalcoholic steatohepatitis. World J Hepatol 2011, 3:15-23.
31. Paradis V., Zalinski S., Chelbi E., et al. Hepatocellular carcinomas in patients with metabolic syndrome often develop without significant liver fibrosis: a pathological analysis. Hepatology 2009, 49:851-859.
32. Yasui K., Hashimoto E., Komorizono Y., et al. Characteristics of patients with nonalcoholic steatohepatitis who develop hepatocellular carcinoma. Clin Gastroenterol Hepatol 2011, 9:428-433.
33. Chen C.L., Yang H.I., Yang W.S., et al. Metabolic factors and risk of hepatocellular carcinoma by chronic hepatitis B/C infection: a follow-up study in Taiwan. Gastroenterology 2008, 135:111-121.
34. Ohki T., Tateishi R., Sato T., et al. Obesity is an independent risk factor for hepatocellular carcinoma development in chronic hepatitis C patients. Clin Gastroenterol Hepatol 2008, 6:459-464.
35. Loomba R., Yang H., Su J., et al. Obesity and alcohol synergize to increase the risk of incident hepatocellular carcinoma in men. Clin Gastroenterol Hepatol 2010, 8:891-898.
36. Nishikawa H., Arimoto A., Wakasa T., et al. The relation between obesity and survival after surgical resection of hepatitis C virus-related hepatocellular carcinoma. Gastroenterol Res Pract 2013, 2013:430438.
37. Mathur A., Franco E.S., Leone J.P., et al. Obesity portends increased morbidity and earlier recurrence following liver transplantation for hepatocellular carcinoma. HPB (Oxford) 2013, 15:504-510.
38. Salomao M., Remotti H., Vaughan R., et al. The steatohepatitic variant of hepatocellular carcinoma and its association with underlying steatohepatitis. Hum Pathol 2012, 43:737-746.
39. Unger R.H., Clark G.O., Scherer P.E., et al. Lipid homeostasis, lipotoxicity and the metabolic syndrome. Biochim Biophys Acta 2010, 1801:209-214.
40. Xu Z., Chen L., Leung L., et al. Liver-specific inactivation of the Nrf1 gene in adult mouse leads to nonalcoholic steatohepatitis and hepatic neoplasia. Proc Natl Acad Sci USA 2005, 102:4120-4125.
41. Yang S.Q., Lin H.Z., Hwang J., et al. Hepatic hyperplasia in noncirrhotic fatty livers is obesity-related hepatic steatosis a premalignant condition?. Cancer Res 2001, 61:5016-5023.
42. Rajala M.W., Scherer P.E. Minireview: the adipocyte-at the crossroads of energy homeostasis, inflammation, and atherosclerosis. Endocrinology 2003, 144:3765-3773.
43. Roberts D.L., Dive C., Renehan A.G. Biological mechanisms linking obesity and cancer risk: new perspectives. Annu Rev Med 2010, 61:301-316.
44. Saxena N.K., Fu P.P., Nagalingam A., et al. Adiponectin modulates C-jun N-terminal kinase and mammalian target of rapamycin and inhibits hepatocellular carcinoma. Gastroenterology 2010, 139:1762-1773.
45. Kitade M., Yoshiji H., Kojima H., et al. Leptin mediated neovascularization is a prerequisite for progression of nonalcoholic steatohepatitis in rats. Hepatology 2006, 44:983-991.
46. Chen C., Chang Y.C., Liu C.L., et al. Leptin induces proliferation and anti-apoptosis in human hepatocarcinoma cells by up-regulating cyclin D1 and down-regulating Bax via a Janus kinase 2-linked pathway. Endocr Relat Cancer 2007, 14:513-529.
47. Marra F., Bertolani C. Adipokines in liver diseases. Hepatology 2009, 50:957-969.
48. Pollak M. Insulin and insulin-like growth factor signaling in neoplasia. Nat Rev Cancer 2008, 8:915-928.
49. Ish-Shalom D., Christoffersen C.T., Vorwerk P., et al. Mitogenic properties of insulin and insulin analogues mediated by the insulin receptor. Diabetologia 1997, 40(Suppl 2):S25-S31.
50. Alexia C., Fallot G., Lasfer M., et al. An evaluation of the role of insulin-like growth factors (IGF) and of type-I IGF receptor signalling in hepatocarcinogenesis and in the resistance of hepatocarcinoma cells against drug-induced apoptosis. Biochem Pharmacol 2004, 68:1003-1015.
51. Park E.J., Lee J.H., Yu G., et al. Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell 2010, 140:197-208.
52. Donadon V., Balbi M., Mas M.D., et al. Metformin and reduced risk of hepatocellular carcinoma in diabetic patients with chronic liver disease. Liver Int 2010, 30:750-758.
53. Yu X.L., Yan H.X., Liu Q., et al. Endotoxin accumulation prevents carcinogen-induced apoptosis and promotes liver tumorigenesis in rodents. Hepatology 2010, 52:1322-1333.
54. Dapito D.H., Mencin A., Gwak G.Y., et al. Promotion of hepatocellular carcinoma by the intestinal microbiota and TLR4. Cancer Cell 2012, 21:504-516.
55. Yoshimoto S., Loo T.M., Atarashi K., et al. Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome. Nature 2013, 499:97-101.
56. Wolk A., Gridley G., Svensson M., et al. Aprospective study of obesity and cancer risk (Sweden). Cancer Causes Control 2001, 12:13-21.
57. Nair S., Mason A., Eason J., et al. Is obesity an independent risk factor for hepatocellular carcinoma in cirrhosis?. Hepatology 2002, 36:150-155.
58. Pan S.Y., Johnson K.C., Ugnat A.M., et al. Association of obesity and cancer risk in Canada. Am J Epidemiol 2004, 159:259-268.
59. Kuriyama S., Tsubono Y., Hozawa A., et al. Obesity and risk of cancer in Japan. Int J Cancer 2005, 113:148-157.
60. Batty G.D., Shipley M.J., Jarrett R.J., et al. Obesity and overweight in relation to organ-specific cancer mortality in London (UK): findings from the original Whitehall study. Int J Obes 2005, 29:1267-1274.
61. Oh S.W., Yoon Y.S., Shin S.A. Effects of excess weight on cancer incidences depending on cancer sites and histologic findings among men: Korea National Health Insurance Corporation Study. JClin Oncol 2005, 23:4742-4754.
62. Rapp K., Schroeder J., Klenk J., et al. Obesity and incidence of cancer: a large cohort study of over 145,000 adults in Austria. Br J Cancer 2005, 93:1062-1067.
63. Samanic C., Chow W.H., Gridley G., et al. Relation of body mass index to cancer risk in 362,552 Swedish men. Cancer Causes Control 2006, 17:901-909.
64. Polesel J., Zucchetto A., Montella M., et al. The impact of obesity and diabetes mellitus on the risk of hepatocellular carcinoma. Ann Oncol 2009, 20:353-357.
65. Regimbeau J.M., Colombat M., Mognol P., et al. Obesity and diabetes as a risk factor for hepatocellular carcinoma. Liver Transpl 2004, 10(2 Suppl 1):S69-S73.
66. Iannaccone R., Piacentini F., Murakami T., et al. Hepatocellular carcinoma in patients with nonalcoholic fatty liver disease: helical CT and MR imaging findings with clinical-pathologic comparison. Radiology 2007, 243:422-430.
67. Hashimoto E., Yatsuji S., Tobari M., et al. Hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. JGastroenterol 2009, 44(Suppl 19):89-95.
68. Ertle J., Dechene A., Sowa J.P., et al. Nonalcoholic fatty liver disease progresses to hepatocellular carcinoma in the absence of apparent cirrhosis. Int J Cancer 2011, 128:2436-2443.
69. Tokushige K., Hashimoto E., Horie Y., et al. Hepatocellular carcinoma in Japanese patients with nonalcoholic fatty liver disease, alcoholic liver disease, and chronic liver disease of unknown etiology: report of the nationwide survey. JGastroenterol 2011, 46:1230-1237.